APA

Heckert J. M., Kipnis S. T., Kumar S., Botterbusch S., Alderson A., Bennett B., Creamer C., Eads J. R., Soulen M. C., Pryma D. A., Mankoff D. A., Metz D. C. & Katona B. W. (20210618). Abnormal Pretreatment Liver Function Tests Are Associated with Discontinuation of Peptide Receptor Radionuclide Therapy in a U.S.-Based Neuroendocrine Tumor Cohort. : The oncologist.

Chicago

Heckert Jason M, Kipnis Sarit T, Kumar Shria, Botterbusch Samuel, Alderson Alice, Bennett Bonita, Creamer Caroline, Eads Jennifer R, Soulen Michael C, Pryma Daniel A, Mankoff David A, Metz David C and Katona Bryson W. 20210618. Abnormal Pretreatment Liver Function Tests Are Associated with Discontinuation of Peptide Receptor Radionuclide Therapy in a U.S.-Based Neuroendocrine Tumor Cohort. : The oncologist.

Harvard

Heckert J. M., Kipnis S. T., Kumar S., Botterbusch S., Alderson A., Bennett B., Creamer C., Eads J. R., Soulen M. C., Pryma D. A., Mankoff D. A., Metz D. C. and Katona B. W. (20210618). Abnormal Pretreatment Liver Function Tests Are Associated with Discontinuation of Peptide Receptor Radionuclide Therapy in a U.S.-Based Neuroendocrine Tumor Cohort. : The oncologist.

MLA

Heckert Jason M, Kipnis Sarit T, Kumar Shria, Botterbusch Samuel, Alderson Alice, Bennett Bonita, Creamer Caroline, Eads Jennifer R, Soulen Michael C, Pryma Daniel A, Mankoff David A, Metz David C and Katona Bryson W. Abnormal Pretreatment Liver Function Tests Are Associated with Discontinuation of Peptide Receptor Radionuclide Therapy in a U.S.-Based Neuroendocrine Tumor Cohort. : The oncologist. 20210618.